Catherine A. Shu, ASCO 2022: Updated results from the CHRYSALIS-2 of amivantamab and lazertinib in patients with advanced NSCLC
Access all of the content
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen.
The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2’ (Abstract: 9006) was presented at the ASCO annual meeting, 3-7 June 2022.
Questions
1. Could you tell us a little about combined therapy with amivantamab and Lazertinib, and the clinical evidence in support of its use?
2. What were the aims and design of the CHRYSALIS-2 study?
3. Which patients were included in cohort A and what were the efficacy findings in this study?
4. What was the safety profile of the combination and what is the importance of this combination?
Disclosures: Catherine A. Shu is a member of the advisory board for AstraZeneca, Mirati Therapeutics, Genentech and Janssen.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.